Bilateral atypical femur fracture in a patient with breast cancer taking zoledronic acid and denosumab: A case report

被引：1

作者：

Hashimoto, Kazuhiko ^{[1
]}

Ito, Tomohiko ^{[1
]}

Yamagishi, Yuto ^{[1
]}

Goto, Koji ^{[1
]}

机构：

[1] Kindai Univ Hosp, Dept Orthoped Surg, Ohnohigashi 377-2, Osaka Sayama City, Osaka 5898511, Japan

来源：

MODERN RHEUMATOLOGY CASE REPORTS | 2024年 / 9卷 / 01期

关键词：

Atypical femoral fracture; bone; breast cancer; denosumab; zoledronic acid; SUPPRESSED BONE TURNOVER; FEMORAL FRACTURES; DOUBLE-BLIND; THERAPY; RISK;

D O I：

10.1093/mrcr/rxae059

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A 54-year-old woman developed stage IV breast cancer 8 years prior. Chemotherapy was administered, and she was started on zoledronic acid treatment for her bone metastases. Her chemotherapy regimen was then switched, owing to disease progression. Fifty-seven months after starting treatment with zoledronic acid, the patient suffered an atypical femoral fracture of her right femur, for which she underwent surgery. Twenty months later, she developed another atypical femoral fracture in her left femur and underwent intramedullary nail fixation.Zoledronic acid and denosumab use in patients with metastatic bone tumours caused by breast cancer should be done cautiously, considering atypical femoral fracture risk.

引用

收藏

页码：41 / 45

页数：5

相关论文

共 27 条

[1]

Agarwal S, 2010, ACTA ORTHOP BELG, V76, P567

[2] Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis [J].

Armamento-Villareal, Reina ;

Napoli, Nicola ;

Panwar, Vinita ;

Novack, Deborah .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (19) :2048-2050

[3] Bisphosphonate treatment and the risk of atypical femoral fracture among patients participating in a Fracture Liaison Service of a tertiary medical center [J].

Bareli, Noa ;

Gat, Roni ;

Makarov, Victoria ;

Siris, Ethel ;

Fraenkel, Merav ;

Yoel, Uri .

ARCHIVES OF OSTEOPOROSIS, 2021, 16 (01)

[4] Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates [J].

Black, Dennis M. ;

Geiger, Erik J. ;

Eastell, Richard ;

Vittinghoff, Eric ;

Li, Bonnie H. ;

Ryan, Denison S. ;

Dell, Richard M. ;

Adams, Annette L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (08) :743-753

[5] Bilateral Low-Energy Simultaneous or Sequential Femoral Fractures in Patients on Long-Term Alendronate Therapy [J].

Capeci, Craig M. ;

Tejwani, Nirmal C. .

JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2009, 91A (11) :2556-2561

[6] Understanding the Bone in Cancer Metastasis [J].

Fornetti, Jaime ;

Welm, Alana L. ;

Stewart, Sheila A. .

JOURNAL OF BONE AND MINERAL RESEARCH, 2018, 33 (12) :2099-2113

[7] Atypical Versus Typical Subtrochanteric Femoral Fractures Disparate Patient Profiles, Similar Outcomes [J].

Gibbons, Kester ;

Merrell, Lauren A. ;

Ganta, Abhishek ;

Rivero, Steven ;

Konda, Sanjit R. ;

Egol, Kenneth A. .

JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2024, 106 (03) :190-197

[8]

Harbeck N, 2017, LANCET, V389, P1134, DOI [10.1016/s0140-6736(16)31891-8, 10.1016/S0140-6736(16)31891-8]

[9] Adverse events associated with bone-directed therapies in patients with cancer [J].

Jara, Mark A. ;

Varghese, Jeena ;

Hu, Mimi I. .

BONE, 2022, 158

[10] Atypical femoral fracture in a bisphosphonate-naive patient on denosumab for osteoporosis [J].

Kumar, Shejil ;

Chang, Ruby ;

Reyes, Michael ;

Diamond, Terrence .

ARCHIVES OF OSTEOPOROSIS, 2022, 17 (01)